India, Aug. 15 -- Shares of Celcuity Inc. (CELC) touched an all-time high of $53.85 in early trading today, building on several eventful months driven by developments surrounding its lead drug candidate, Gedatolisib.
Gedatolisib is a potent, pan-PI3K and mTORC1/2 inhibitor being developed for the treatment of patients with HR+/HER2-advanced breast cancer. Celcuity obtained the rights to this drug candidate through a licensing agreement with Pfizer, signed in April 2021.
A phase III trial evaluating Gedatolisib in combination with fulvestrant, with and without palbociclib, in patients with HR+/HER2-advanced breast cancer who have received prior treatment with a CDK4/6 inhibitor, dubbed VIKTORIA-1, is underway. The study includes two cohort...